The prospect of precision therapy for renal cell carcinoma

Area of Science:

• Oncology
• Metabolic Diseases
• Cancer Biology

Background:

• Renal cell carcinoma (RCC) treatment has evolved significantly, moving from limited options to a broader therapeutic landscape.
• RCC is fundamentally a metabolic disease characterized by dysregulated oxygen, energy, and nutrient sensing pathways.
• Key metabolic alterations include VHL/HIF pathway dysregulation, Warburg effect, and aberrant signaling cascades (e.g., mTOR, AMPK).

Purpose of the Study:

• To highlight the metabolic underpinnings of renal cell carcinoma (RCC).
• To underscore the importance of identifying prognostic and predictive factors in managing metastatic RCC (mRCC).

Main Methods:

• Review of current understanding of RCC metabolic pathways.
• Analysis of key signaling cascades involved in RCC pathogenesis.
• Discussion of the role of metabolic dysregulation in cancer progression.

Main Results:

• RCC exhibits characteristic metabolic dysregulations, including altered oxygen sensing (VHL/HIF), energy sensing (e.g., FH-deficient RCC, MET pathway mutations), and nutrient sensing (mTOR, AMPK pathways).
• These metabolic shifts promote aerobic glycolysis, pentose phosphate shunt activity, and lipogenesis, while reducing Krebs cycle function.
• The identified metabolic characteristics provide a basis for understanding RCC's therapeutic vulnerabilities.

Conclusions:

• Understanding the metabolic complexity of RCC is essential for advancing treatment strategies.
• Prognostic and predictive factors related to these metabolic pathways are critical for optimizing patient management in metastatic RCC.